Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2016

Metoreksat-yetersiz Yanıtlı Orta ve Ciddi Romatoid Artrit Tedavisinde bir JAK Inhibitörü Peficitinib

Arthritis & Rheum 2016; ePub ahead of print

Shay K,

Wang X,

Garg JP,

Zubrzycka-Sienkiewicz A

This Phase 2b study of peficitinib (ASP015K), an orally administered once-daily JAK inhibitor, plus MTX, demonstrated efficacy across multiple secondary endpoints with higher peficitinib doses. Peficitinib in combination with MTX was well tolerated with a safety profile that was consistent with previous studies.A high placebo response rate was seen in both Latin and North America, when patient data were stratified. This high placebo rate is problematic for the accurate interpretation of peficit...

Keywords:

RA Hastalarında VX-509 (Decernotinib) ve Hastalığı Modifiye Edici Bir Antiromatizmal İlaç Kombinasyonunun Etkinliği: Klinik ve MR Bulguları

Ann Rheum Dis 2016;75:1979–83

Genovese M,

Yang F,

Østergaard M and Kinnman N

This Phase 2b study of VX-509 (decernotinib), a selective JAK3 inhibitor, showed that VX-509 in combination with stable DMARD therapy was effective for improving synovitis and osteitis as assessed by MRI in patients who had an inadequate response to DMARD therapy.Patients were randomised to treatment groups receiving either placebo, VX-509 100 mg, 200 mg or300 mg for 12 weeks. Minimum inclusion criteria included Grade ≥2 clinical synovitis in either the wrist or two metacarpophalangeal joints. A...

Keywords:

October 2016

Sarilumab ve Metotreksat Kombinasyonu Metotreksata Yetersiz Yanıtlı Aktif Romatoid Artrit Hastalarında Hasta Tarafından Bildirilen Sonuçları (PRO) İyileştirir: Bir Faz III Çalışmanın Sonuçları

Arthritis Res Ther 2016; 18:198. DOI.10.1186/s13075-016-9

Fan C,

Evidence is presented that treatment with sarilumab improves patient-reported outcomes (PROs). These improvements complement the clinical efficacy previously reported for sarilumab.Data were analysed from the 52-week Phase 3 MOBILITY randomised controlled trial in adult patients with active RA and previous inadequate response to MTX. Patients received subcutaneous placebo or sarilumab 150 mg or 200 mg every 2 weeks in combination with MTX, for 52 weeks.PROs assessed were: Patient Global Assessme...

Keywords:

August 2016

Metotreksata Yetersiz Yanıtlı Romatoid Artrit Hastalarında Seçici Bir JAK İnhibitörü olan ABT-494'ün Randomize Faz 2b Çalışması

Arthritis Rheumatol 2016; Accepted article DOI 10.1002/art-39808 [Epub 2016]

Camp H,

Wang L,

Othman A,

Khan N,

Pangan A,

Jungerwirth S

This dose-ranging study evaluated the efficacy of the novel, selective JAK1 inhibitor ABT-494 versus placebo in patients with moderate-to-severe RA and inadequate response (IR) to MTX.In this 12-week, randomised, double-blind study (BALANCE II), the efficacy and safety ofABT-494 dosed at 3mg, 6 mg, 12 mg, 18 mg (all twice daily) and 24 mg (once daily) was assessed. Patients included had not received prior biologic therapy.Of the 299 patients included in the analysis, the proportions of patients ...

Keywords:

January 2016

Romatoid Artritde Oral Selektif JAK-3 Inhibitorü VX-509 (Decernotinib) ve Metotreksat Kombinasyonu

Arthritis Rheumatol. 2016 Jan;68(1):46-55.

Zhang Y,

VX-509 (decernotinib) is a novel oral, selective inhibitor of JAK-3. JAK-3 is a member of the JAK signalling family that is primarily expressed in hematopoietic cells and associates with only the common γ-chain making it a promising therapeutic drug target. A phase IIb 24-week study of VX-509 in 358 patients with RA, who had prior inadequate response to MTX, uses ACR20 response rate and DAS28-CRP change at Week 12 to assess the efficacy of VX-509. Patients were administered either placebo+MTX or...